We are very pleased to announce that Dr. Robert Stephan has recently joined The Arcas Group as Director, Medical Services and Strategy. He has already proven to be a great addition to our leadership team.
Rob joins Arcas with more than 15 years of experience in oncology, hematology, and immunology research and continuing medical education program development and implementation, with a specialization in strategic planning and execution.
Focusing on managing and expanding the relationships of Arcas with global and national thoughtleaders in complex disease areas, Rob deepens the clinical and scientific expertise of our team. He will play an instrumental role and be a key driver to support the continued growth of Arcas. Rob’s bio can be viewed here.
View your invitation by clicking on the image:
You are invited to join the MDOUTLOOK Strategy Council to discuss cancer treatment from a clinician’s point of view. Events will be scheduled on 12-15 September at the Stockholm International Fairs, where ESMO is being held. We will accommodate your schedule for convenient meeting times.
We look forward to seeing you at ESMO. For complete details and RSVP, please contact Craig Krugman, Vice President, Client Services & Strategy at +1.404.452.5988, [email protected]earcasgroup.com. You can also contact Walter Colasante, Director, European Strategic Development at +44.1638.718460, [email protected].
MDOUTLOOK is an exclusive web-based platform that provides a clinical practitioner’s view of the European and United States oncology landscape.
· Insight into clinical treatment behavior – with a singular focus on treatment decisions and rationale
· Exclusive access to unique ThoughtLeader driven analysis, intelligence and perspective
· Comprehensive profiles of cancer treaters, ThoughtLeaders and institutions.
The MDOUTLOOK Strategy Council will be on hand to privately discuss the landscape of cancer treatment, and to demonstrate how MDOUTLOOK delivers critical marketing intelligence and insight that will directly contribute to your commercial success.